Abstract
The phospholipase A2 (PLA2) superfamily consists of different groups of enzymes which are characterized by their ability to catalyze the hydrolysis of the sn-2 ester bond in a variety of phospholipid molecules. The products of PLA2s activity play divergent roles in a variety of physiological processes. There are four main types of PLA2s: the secreted PLA2s (sPLA2s), the cytosolic PLA2s (cPLA2s), the calcium-independent PLA2s (iPLA2) and the lipoprotein-associated PLA2s (LpPLA2s). Various potent and selective PLA2 inhibitors have been reported up to date and have provided outstanding support in understanding the mechanism of action and elucidating the function of these enzymes. The current review focuses on the implementation of rational design through computer-aided drug design (CADD) on the discovery and development of new PLA2 inhibitors.
Keywords: Computer-aided drug design, inhibitors, phospholipases A2, rational design, PLA2, enzymes, hydrolysis, phospholipid, iPLA2, LpPLA2s
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
11